{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:41:41Z","timestamp":1790534501574,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor (CAR) T-cell therapies have demonstrated high response rates in patients with relapsed\/refractory large B-cell lymphoma (LBCL); however, these therapies are associated with 2 CAR T cell\u2013specific potentially severe adverse events (AEs): cytokine release syndrome (CRS) and neurological events (NEs). This study estimated the management costs associated with CRS\/NEs among patients with relapsed\/refractory LBCL using data from the pivotal TRANSCEND NHL 001 trial of lisocabtagene maraleucel, an investigational CD19-directed defined composition CAR T-cell product with a 4-1BB costimulation domain administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This retrospective analysis of patients from TRANSCEND with prospectively identified CRS and\/or NE episodes examined relevant trial-observed health care resource utilization (HCRU) associated with toxicity management based on the severity of the event from the health care system perspective. Cost estimates for this analysis were taken from publicly available databases and published literature. Of 268 treated patients as of April 2019, 127 (47.4%) experienced all-grade CRS and\/or NEs, which were predominantly grade \u22642 (77.2%). Median total AE management costs ranged from $1930 (grade 1 NE) to $177\u2009343 (concurrent grade \u22653 CRS and NE). Key drivers of cost were facility expenses, including intensive care unit and other inpatient hospitalization lengths of stay. HCRU and costs were significantly greater among patients with grade \u22653 AEs (22.8%). Therefore, CAR T-cell therapies with a low incidence of severe CRS\/NEs will likely reduce HCRU and costs associated with managing patients receiving CAR T-cell therapy. This clinical trial was registered at www.clinicaltrials.gov as #NCT02631044.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003531","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T15:35:04Z","timestamp":1615822504000},"page":"1695-1705","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel\u2013treated patients in the TRANSCEND NHL 001 trial"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Garcia","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dehner","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonhee","family":"Kim","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Snyder","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"November","family":"McGarvey","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gitlin","sequence":"additional","affiliation":[{"name":"BluePath Solutions, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika P.","family":"Jun","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"2021031815154240300_B1","article-title":"US Cancer Statistics data visualizations tool, based on November 2018 submission data (1999-2016)","author":"US Cancer Statistics Working Group"},{"issue":"8","key":"2021031815154240300_B2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021031815154240300_B3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2021031815154240300_B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"2021031815154240300_B5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2021031815154240300_B6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2021031815154240300_B7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/14712598.2016.1229773","article-title":"Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation","volume":"16","author":"Fedele","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"2021031815154240300_B8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3747\/co.26.5421","article-title":"Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma","volume":"26","author":"Skrabek","year":"2019","journal-title":"Curr Oncol"},{"issue":"26","key":"2021031815154240300_B9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2021031815154240300_B10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"2021031815154240300_B11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2021031815154240300_B12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published corrections appear in Blood. 2015;126(8):1048 and Blood. 2016;128(11):1533]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2021031815154240300_B13","author":"Siddiqi","year":"2018"},{"key":"2021031815154240300_B14","author":"Abramson","year":"2019"},{"issue":"4","key":"2021031815154240300_B15","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2021031815154240300_B16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021031815154240300_B17","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","author":"US Department of Health and Human Services"},{"key":"2021031815154240300_B18","article-title":"Strengthening the Reporting of Observational studies in Epidemiology (STROBE). STROBE statement: checklist of items that should be included in reports of cohort studies","author":"University of Bern"},{"key":"2021031815154240300_B19","article-title":"National Inpatient Sample. Healthcare Cost and Utilization Project","author":"Agency for Healthcare Research and Quality"},{"key":"2021031815154240300_B20","article-title":"Medicare physician fee schedule","author":"Centers for Medicare and Medicaid Services"},{"key":"2021031815154240300_B21","article-title":"Hospital Outpatient Prospective Payment System","author":"Centers for Medicare and Medicaid Services"},{"key":"2021031815154240300_B22","author":"Centers for Medicare and Medicaid Services"},{"key":"2021031815154240300_B23","article-title":"Clinical laboratory fee schedule","author":"Centers for Medicare and Medicaid Services"},{"key":"2021031815154240300_B24","article-title":"IBM Micromedex RED BOOK","author":"IBM Watson Health Product Education"},{"issue":"6","key":"2021031815154240300_B25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.CCM.0000164543.14619.00","article-title":"Daily cost of an intensive care unit day: the contribution of mechanical ventilation","volume":"33","author":"Dasta","year":"2005","journal-title":"Crit Care Med"},{"key":"2021031815154240300_B26","article-title":"Consumer price index for all urban consumers: medical care in the U.S. city average [CPIMEDNS], retrieved from FRED, Federal Researve Band of St. Louis","author":"US Bureau of Labor Statistics"},{"key":"2021031815154240300_B27","article-title":"Fact sheet: underpayment by Medicare and Medicaid","author":"American Hospital Association"},{"key":"2021031815154240300_B28","article-title":"Cancer treatment costs are consistently lower in the community setting versus the hospital outpatient department","author":"Leavitt Partners"},{"issue":"9","key":"2021031815154240300_B29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.bmt.1701191","article-title":"Reduced charges and costs associated with outpatient autologous stem cell transplantation","volume":"21","author":"Meisenberg","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2021031815154240300_B30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2021031815154240300_B31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J Med Econ"},{"issue":"24","key":"2021031815154240300_B32","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021031815154240300_B33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States [published correction appears in J Med Econ. 2018;21(12):1255]","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"issue":"2","key":"2021031815154240300_B34","doi-asserted-by":"crossref","first-page":"e190035","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2021031815154240300_B35","article-title":"Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value.","author":"Institute for Clinical and Economic Review"},{"key":"2021031815154240300_B36","article-title":"YESCARTA (axicabtagene ciloleucel) prescribing information","author":"Kite Pharma"},{"key":"2021031815154240300_B37","article-title":"KYMRIAH (tisagenlecleucel) prescribing information","author":"Novartis Pharmaceuticals Corporation"},{"issue":"4","key":"2021031815154240300_B38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL\u201d","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2021031815154240300_B39","author":"Nguyen"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1695\/1803361\/advancesadv2020003531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1695\/1803361\/advancesadv2020003531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:16:04Z","timestamp":1616080564000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/6\/1695\/475479\/Cytokine-release-syndrome-and-neurological-event"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003531","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}